Progression to castration-resistance and metastatic disease following androgen deprivation therapy for biochemical recurrence after prostate cancer surgery.
BACKGROUND Biochemical recurrence after radical prostatectomy for localized prostate cancer impacts nearly one in four patients. While androgen deprivation therapy (ADT) is used in this setting, its impact on metastatic disease outcomes remains unclear in contemporary population-based cohorts. METHODS We performed a...